Digital Pathology Supports ADC Development

With almost 20 already approved since 2000, including some blockbusters, antibody drug conjugates (ADCs) are clearly one of the biggest waves in cancer research. But even the older, less complicated, targeted therapies, including pioneer Herceptin that targets HER2, have had their challenges in the testing lab. Pathologists hunched over microscope slides sometimes had difficulty coming to the same conclusions. Now, experts are betting that AI-driven digital pathology can make the ADC revolution go more smoothly.

“We are at the tip of the iceberg with ADCs, and digital pathology opens new frontiers,” Jeff Allen, PhD, president and CEO of Friends of Cancer Research told Inside Precision Medicine . “Tumors can be targeted more efficiently and targets that were unrecognizable before wi